Development of a Novel Heart Failure Risk Tool: The Barcelona Bio-Heart Failure Risk Calculator (BCN Bio-HF Calculator)

被引:96
作者
Lupon, Josep [1 ,2 ]
de Antonio, Marta [1 ,2 ]
Vila, Joan [3 ,4 ]
Penafiel, Judith [3 ,4 ]
Galan, Amparo [5 ]
Zamora, Elisabet [1 ,2 ]
Urrutia, Agustin [1 ,2 ]
Bayes-Genis, Antoni [1 ,2 ]
机构
[1] Hosp Badalona Germans Trias & Pujol, Heart Failure Unit, Badalona, Spain
[2] Autonomous Univ Barcelona, Dept Med, Barcelona, Spain
[3] Hosp del Mar Med Res Inst IMIM, Barcelona, Spain
[4] CIBER Epidemiol & Publ Hlth, Barcelona, Spain
[5] Hosp Badalona Germans Trias & Pujol, Serv Biochem, Badalona, Spain
来源
PLOS ONE | 2014年 / 9卷 / 01期
关键词
PREDICTING MORTALITY; AMBULATORY PATIENTS; TROPONIN-T; SURVIVAL; VALIDATION; BIOMARKERS; DISCRIMINATION; PERFORMANCE; PROGNOSIS; SCORE;
D O I
10.1371/journal.pone.0085466
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: A combination of clinical and routine laboratory data with biomarkers reflecting different pathophysiological pathways may help to refine risk stratification in heart failure (HF). A novel calculator (BCN Bio-HF calculator) incorporating N-terminal pro B-type natriuretic peptide (NT-proBNP, a marker of myocardial stretch), high-sensitivity cardiac troponin T (hs-cTnT, a marker of myocyte injury), and high-sensitivity soluble ST2 (ST2), (reflective of myocardial fibrosis and remodeling) was developed. Methods: Model performance was evaluated using discrimination, calibration, and reclassification tools for 1-, 2-, and 3-year mortality. Ten-fold cross-validation with 1000 bootstrapping was used. Results: The BCN Bio-HF calculator was derived from 864 consecutive outpatients (72% men) with mean age 68.2 +/- 12 years (73%/27% New York Heart Association (NYHA) class I-II/III-IV, LVEF 36%, ischemic etiology 52.2%) and followed for a median of 3.4 years (305 deaths). After an initial evaluation of 23 variables, eight independent models were developed. The variables included in these models were age, sex, NYHA functional class, left ventricular ejection fraction, serum sodium, estimated glomerular filtration rate, hemoglobin, loop diuretic dose, beta-blocker, Angiotensin converting enzyme inhibitor/Angiotensin-2 receptor blocker and statin treatments, and hs-cTnT, ST2, and NT-proBNP levels. The calculator may run with the availability of none, one, two, or the three biomarkers. The calculated risk of death was significantly changed by additive biomarker data. The average C-statistic in cross-validation analysis was 0.79. Conclusions: A new HF risk-calculator that incorporates available biomarkers reflecting different pathophysiological pathways better allowed individual prediction of death at 1, 2, and 3 years.
引用
收藏
页数:8
相关论文
共 23 条
  • [1] Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation
    Aaronson, KD
    Schwartz, JS
    Chen, TM
    Wong, KL
    Goin, JE
    Mancini, DM
    [J]. CIRCULATION, 1997, 95 (12) : 2660 - 2667
  • [2] Predictors of in-hospital mortality in patients hospitalized for heart failure - Insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF)
    Abraham, William T.
    Fonarow, Gregg C.
    Albert, Nancy M.
    Stough, Wendy Gattis
    Gheorghiade, Mihai
    Greenberg, Barry H.
    O'Connor, Christopher M.
    Sun, Jie Lena
    Yancy, Clyde W.
    Young, James B.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 52 (05) : 347 - 356
  • [3] [Anonymous], 2009, ENCY DATABASE SYSTEM, DOI DOI 10.1007/978-0-387-39940-9_565
  • [4] Combined use of high-sensitivity ST2 and NTproBNP to improve the prediction of death in heart failure
    Bayes-Genis, Antoni
    de Antonio, Marta
    Galan, Amparo
    Sanz, Hector
    Urrutia, Agustin
    Cabanes, Roser
    Cano, Lucia
    Gonzalez, Beatriz
    Diez, Cristanto
    Pascual, Teresa
    Elosua, Roberto
    Lupon, Josep
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2012, 14 (01) : 32 - 38
  • [5] Biomarkers in heart failure
    Braunwald, Eugene
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (20) : 2148 - 2159
  • [6] A multivariate model for predicting mortality in patients with heart failure and systolic dysfunction
    Brophy, JM
    Dagenais, GR
    McSherry, F
    Williford, W
    Yusuf, S
    [J]. AMERICAN JOURNAL OF MEDICINE, 2004, 116 (05) : 300 - 304
  • [7] Collet D, 1995, MODELLING SURVIVAL D, P107
  • [8] D'Agostino RB, 2004, HANDB STAT, V23, P1
  • [9] Combined use of high-sensitivity cardiac troponin T and N-terminal pro-B type natriuretic peptide improves measurements of performance over established mortality risk factors in chronic heart failure
    de Antonio, Marta
    Lupon, Josep
    Galan, Amparo
    Vila, Joan
    Urrutia, Agustin
    Bayes-Genis, Antoni
    [J]. AMERICAN HEART JOURNAL, 2012, 163 (05) : 821 - 828
  • [10] Improvements on cross-validation: The .632+ bootstrap method
    Efron, B
    Tibshirani, R
    [J]. JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1997, 92 (438) : 548 - 560